Bullish Case: CDNA trades near $36.36 after earlier upside catalysts (lab-product sale completion; solid-organ LCD finalized July 16). The CDNA return-surface likelihood concentrates around modest returns, and the IV surface’s highest “red” is mainly deep downside puts (tail-priced). A Q2 beat or guide raise on Jul 30 (with evidence of LCD uptake ahead of Aug 30) could flip put-demand to call-demand, yielding a modest +10–25% repricing.

Bearish Case: Known: CDNA options sit in backwardation and the CDNA IV surface shows persistent, very high implied vols on low strikes across ~28–190 days (dealer hedging for a downside tail). Inferred: with price recently flat, the market may be waiting for Jul 30 earnings to confirm/deny reimbursement and cash-flow durability. If guidance language weakens (or 2H revenue/EPS are cut), unwinds can push -10% to -30%, consistent with the non-zero negative-return mass on the CDNA return surface.

Potential Outcomes:

1. 45% Flat/limited move: Q2 results + guidance broadly inline; falsify by guide change vs consensus >10%.
2. 28% Bear drift (-10–25%): reimbursement/test-volume adoption disappointment; falsify by lowered 2H revenue/EPS.
3. 12% Bull rebound (+10–25%): beat/raise with LCD traction pre–Aug 30; falsify by explicit 2H guide raise.
4. 10% Crash (-30–50%): cash/AR or regulatory setback; falsify by liquidity warnings/negative regulatory language.
5. 5% Bull spike (+30–60%): surprise partnership/M&A re-rate; falsify by 8-K/PR with material terms.

Oracle: after Jul 30, a downside-tail case is supported if put IV stays elevated without price recovery above ~$35.

July 28, 2026